Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Chromosomal Instability In Cell-Free DNA As A Highly Specific Biomarker For Detection Of Ovarian Cancer In Women With Adnexal Masses

A. Vanderstichele, P. Busschaert, D. Smeets, C. Landolfo, E. van Nieuwenhuysen, K. Leunen, P. Neven, F. Amant, S. Mahner, E. Braicu, R. Zeilinger, A. Coosemans, D. Timmerman, D. Lambrechts, I. Vergote
Published 2016 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Purpose: Chromosomal instability is a hallmark of ovarian cancer. Here, we explore copy-number alteration (CNA) profiling in cell-free DNA as a potential biomarker to detect malignancy in patients presenting with an adnexal mass. Experimental Design: We prospectively enrolled 68 patients with an adnexal mass, of which 57 were diagnosed with invasive or borderline carcinoma and 11 with benign disease. Cell-free DNA was extracted from plasma and analyzed by low-coverage whole-genome sequencing. Results: Patterns of chromosomal instability were detectable in cell-free DNA using 44 healthy individuals as a reference. Profiles were representative of those observed in matching tumor tissue and contained CNAs enriched in two large datasets of high-grade serous ovarian cancer (HGSOC). Quantitative measures of chromosomal instability, referred to as genome-wide z-scores, were significantly higher in patients with ovarian carcinoma than in healthy individuals or patients with benign disease. Cell-free DNA testing improved malignancy detection (AUC 0.89) over serum CA-125 (AUC 0.78) or the risk of malignancy index (RMI, AUC 0.81). AUC values of cell-free DNA testing even further increased for HGSOC patients specifically (AUC 0.94). At a specificity of 99.6%, a theoretical threshold required for ovarian cancer screening, sensitivity of cell-free DNA testing was 2- to 5-fold higher compared with CA-125 and RMI testing. Conclusions: This is the first study evaluating the potential of cell-free DNA for the diagnosis of primary ovarian cancer using chromosomal instability as a read-out. We present a promising method to increase specificity of presurgical prediction of malignancy in patients with adnexal masses. Clin Cancer Res; 23(9); 2223–31. ©2016 AACR.
This paper references
10.1186/gm434
Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing
E. Heitzer (2013)
Fast and accurate short read alignment with BurrowsWheeler transform
H Li (2009)
Lambrechts, I. Vergote Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases
A Vanderstichele (2012)
10.1016/0020-7292(91)90345-6
A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer
I. Jacobs (1990)
10.1097/IGC.0000000000000089
Epithelial Ovarian Cancer: Rationale for Changing the One-Fits-All Standard Treatment Regimen to Subtype-Specific Treatment
E. Despierre (2014)
10.1038/bjc.1993.517
Ovarian Cancer
I. Judson (1993)
10.18637/JSS.V028.I05
Building Predictive Models in R Using the caret Package
M. Kuhn (2008)
10.1097/01.OGX.0000473791.14913.B7
Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies
D. Bianchi (2015)
10.1373/clinchem.2014.226571
Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer.
E. Schütz (2015)
10.1016/S2352-3026(14)00039-8
Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study.
P. Vandenberghe (2015)
10.1038/nature12065
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
M. Murtaza (2013)
Ovarian cancer screening and early detection in the general population.
J. A. Rauh-Hain (2011)
10.1371/journal.pone.0145754
Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers
E. Pereira (2015)
10.1016/j.ajog.2008.04.009
The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
V. Nossov (2008)
10.1016/j.ejca.2016.01.007
Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis.
E. Meys (2016)
10.1073/pnas.1009843107
Allele-specific copy number analysis of tumors
P. Van Loo (2010)
10.3322/caac.21262
Global cancer statistics, 2012
L. Torre (2015)
10.1093/bioinformatics/btv191
Stratifying tumour subtypes based on copy number alteration profiles using next-generation sequence data
A. Gusnanto (2015)
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial. Lancet 2015;387:945–56
IJ Jacobs (2017)
ACOG Practice Bulletin. Management of adnexal masses.
(2007)
10.1001/jama.2011.766
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
S. Buys (2011)
10.1002/uog.12323
Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies
J. Kaijser (2013)
10.1158/1078-0432.CCR-14-1292
Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver
C. Emmanuel (2014)
10.1101/gr.175141.114
DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly.
I. Scheinin (2014)
10.1016/j.ygyno.2013.11.030
Ovarian cancer screening—Current status, future directions☆
U. Menon (2014)
10.1016/j.lungcan.2015.07.002
Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
S. Xia (2015)
10.1093/bioinformatics/btp324
Fast and accurate short read alignment with Burrows–Wheeler transform
Heng Li (2009)
10.1016/S0140-6736(15)01224-6
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
I. Jacobs (2016)
10.1038/ng.2762
Emerging landscape of oncogenic signatures across human cancers
Giovanni Ciriello (2013)
10.1093/bioinformatics/btp352
The Sequence Alignment/Map format and SAMtools
Heng Li (2009)
10.1007/s10555-013-9429-5
The detection and implication of genome instability in cancer
L. Pikor (2013)
10.1016/j.ygyno.2014.09.014
Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer.
E. Despierre (2014)
10.1093/nar/gkv111
TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer
J. Chien (2015)
10.1001/jamaoncol.2015.1883
Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing.
F. Amant (2015)
10.1038/nature10166
Integrated Genomic Analyses of Ovarian Carcinoma
D. Bell (2011)
10.1093/humupd/dmt059
Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis.
J. Kaijser (2014)
10.1126/scitranslmed.3004742
Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing
Rebecca J. Leary (2012)
10.18637/JSS.V028.C01
Beanplot: A Boxplot Alternative for Visual Comparison of Distributions
P. Kampstra (2008)
10.1371/journal.pgen.1004271
Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing
S. Mohan (2014)
10.1016/j.ajog.2016.01.007
Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group.
D. Timmerman (2016)
Ovarian Cancer: American Cancer Society Atlas of Clinical Oncology
R. Ozols (2003)
10.1093/bioinformatics/bti623
ROCR: visualizing classifier performance in R
T. Sing (2005)



This paper is referenced by
10.18632/oncotarget.27418
Circulating tumor DNA analysis in the era of precision oncology
Rabih Said (2020)
10.1186/s13048-017-0369-5
Circulating cell-free DNA and circulating tumor cells, the “liquid biopsies” in ovarian cancer
Xianliang Cheng (2017)
10.1038/s41598-018-29381-y
Massively parallel sequencing of cell-free DNA in plasma for detecting gynaecological tumour-associated copy number alteration
M. Nakabayashi (2018)
10.1186/s13039-019-0429-1
The emerging links between chromosomal instability (CIN), metastasis, inflammation and tumour immunity
Andréa E. Tijhuis (2019)
10.1158/1078-0432.CCR-17-0675
Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients
N. Van Roy (2017)
10.1007/s00428-018-2447-5
Circulating tumor cells and cell-free nucleic acids in patients with gynecological malignancies
B. Davidson (2018)
10.1002/uog.18951
Differences in ultrasound features of papillations in unilocular‐solid adnexal cysts: a retrospective international multicenter study
C. Landolfo (2018)
10.3390/cancers11050641
Acute Tumor Transition Angle on Computed Tomography Predicts Chromosomal Instability Status of Primary Gastric Cancer: Radiogenomics Analysis from TCGA and Independent Validation
Y. Lai (2019)
10.1111/joim.12897
Cell‐free tumour DNA testing for early detection of cancer – a potential future tool
G. Barbany (2019)
10.17925/USE.2019.15.1.39
Liquid Biopsies in Endocrine Neoplasia—A Systematic Review
Theresa R Tonozzi (2019)
10.1186/s13048-020-00729-1
Prediction of the treatment response in ovarian cancer: a ctDNA approach
M. Sharbatoghli (2020)
10.1101/2021.01.05.425414
LiquidCNA: tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations
Eszter Lakatos (2021)
10.2147/OTT.S227156
Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer
Q. Chen (2019)
10.3390/diagnostics7020032
Validation of the Performance of International Ovarian Tumor Analysis (IOTA) Methods in the Diagnosis of Early Stage Ovarian Cancer in a Non-Screening Population
W. Froyman (2017)
10.1017/erm.2018.5
Potential clinical applications of circulating cell-free DNA in ovarian cancer patients.
Ana Barbosa (2018)
10.1016/J.BULCAN.2018.11.018
Apports de l’ADN tumoral circulant dans la compréhension et la prise en charge des carcinomes d’origine gynécologique
Roxane Mari (2019)
10.18632/oncotarget.17397
Implementing liquid biopsies into clinical decision making for cancer immunotherapy
Dagmar Quandt (2017)
10.1053/J.SULT.2019.03.003
Cervical, Ovarian and Endometrial Tumor Markers: Potential Clinical Value.
Carolina Malhone (2019)
10.1016/j.canlet.2019.10.014
Liquid biopsy in Ovarian cancer using Circulating Tumor DNA and Cells: Ready for Prime Time?
D. Asante (2019)
10.1016/bs.acc.2020.01.001
Liquid biopsy in ovarian cancer.
Lydia Giannopoulou (2020)
10.1016/j.drudis.2018.07.008
Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology.
Demosthenes E Ziogas (2018)
10.1002/ijc.33182
miR‐181a overexpression predicts the poor treatment response and early‐progression of serous ovarian cancer patients
Konstantina Panoutsopoulou (2020)
10.3390/cancers11060774
Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease
Roxane Mari (2019)
10.1515/cclm-2017-0019
Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA
Lydia Giannopoulou (2018)
10.1089/biores.2019.0031
Comparison of Somatic Mutation Profiles Between Formalin-Fixed Paraffin Embedded Tissues and Plasma Cell-Free DNA from Ovarian Cancer Patients Before and After Surgery
Marianna Jagelková (2020)
10.1158/1078-0432.CCR-18-1593
Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort
Xiaoji Chen (2019)
10.3390/medicines5010016
Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells
U. Testa (2018)
10.1016/j.ygyno.2020.09.025
Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
C. Landolfo (2020)
10.1016/j.gene.2019.143993
Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis.
B. Li (2019)
10.1016/j.hoc.2018.07.003
Early Detection of Ovarian Cancer.
K. Elias (2018)
10.3389/fdgth.2020.573010
Non-invasive Technology Advances in Cancer—A Review of the Advances in the Liquid Biopsy for Endometrial and Ovarian Cancers
M. Openshaw (2020)
Semantic Scholar Logo Some data provided by SemanticScholar